Oncosil Medical (OSL) Q3 2025 TU earnings summary

Executive summary

• Achieved record quarterly dose sales in Q3 FY25, with a 233% increase over Q3 FY24 and an 83% YTD increase, driving a 135% uplift in YTD revenues.

• Revenue for the nine months to end-Q3 FY25 already exceeds all of FY24, reflecting strong commercial momentum.

• Major regulatory and commercial milestones reached, including MDR approval and expanded hospital access in Europe.

• Strategic Advisory Board meetings in the UK and Germany defined pathways for device advancement and market positioning.

Financial highlights

• Receipts from customers totaled $220k for the quarter and $622k YTD.

• Net cash used in operating activities was $(2.98)m for the quarter and $(9.15)m YTD.

• Received $1.05m R&D tax incentive in Q3 FY25.

• Raised $10.93m from equity securities YTD, with net cash from financing activities at $10.08m.

• Cash and cash equivalents at quarter end were $5.44m.

Outlook and guidance

• Strong sales growth in FY25 expected to be more fully reflected in future revenue due to payment lags.

• Operational efficiencies from MDR approval anticipated to deliver substantial cost savings over the next three years, to be reinvested in growth.

• Board expects to continue operations and meet objectives, with plans for prudent cash management and potential further capital raises.